Amerise Biosciences Ltd Stock Price Today (NSE: AMERISE)

Amerise Biosciences Ltd

0.71+0.03 (+4.41%)
Market Closed

Fundamental Score

...

Amerise Biosciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Amerise Biosciences Ltd share price today is 0.71, up +4.41% on NSE/BSE as of 19 June 2026. Amerise Biosciences Ltd (AMERISE) is a Small-cap company in the Plastic Products - Industrial sector with a market capitalisation of 3.97 (Cr). The 52-week high for AMERISE share price is 0.92 and the 52-week low is 0.50. At a P/E ratio of 99.19x, AMERISE is currently trading above its industry average P/E of 23.37x. The company has a Return on Equity (ROE) of 0.19% and a debt-to-equity ratio of 0.00.

Amerise Biosciences Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
0.80
Low
0.68
Volume
64.5K
Change
-1.39%

Amerise Biosciences Ltd share price chart: -1.39% return over the past month. 52-week high ₹0.92, 52-week low ₹0.50.

Amerise Biosciences Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
0.670.710.670.7150.84K (Cr)
0.710.710.680.6815.53K (Cr)
0.690.710.690.719.81K (Cr)
0.710.710.710.7140.95K (Cr)
0.710.710.710.7121.79K (Cr)
0.690.710.690.7112.68K (Cr)
0.710.710.680.682.11L (Cr)
0.740.740.710.719.66K (Cr)
0.740.740.740.747.68K (Cr)
0.710.740.710.7411.84K (Cr)

Amerise Biosciences Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
0.710.710.670.71+0.00%
0.700.800.680.71+1.43%
0.590.780.590.69+16.95%
0.690.720.500.59-14.49%
0.610.840.600.70+14.75%
0.610.700.530.61+0.00%
0.620.700.510.61-1.61%
0.630.730.550.62-1.59%
0.650.710.550.63-3.08%
0.780.780.650.65-16.67%
0.700.790.690.69-1.43%
0.850.920.670.70-17.65%

AI Research Briefing

Powered by Gemini · 2026-04-09

This is a zero-revenue zombie stock trading on hope; avoid at all costs.

Research Confidence
9.0/10High
MICRO-CAP DARK HORSE1M: +10.00%, 3M: +4.76% - likely driven by speculative buying.Expensive. P/E is 66x, but on what earnings? Industry P/E is 23.37x, making it significantly overvalued compared to its peers.

WHAT'S HAPPENING NOW (last 2-4 weeks)

No major catalysts found after live search. The The market is likely pricing in hope of a turnaround or acquisition, despite zero revenue.

WHAT IS DRIVING THE STOCK

Micro-cap speculation: Low price attracts retail investors hoping for a quick buck.

'Recovery Setup Building' narrative: Despite no fundamental change, old articles suggest some are betting on a turnaround.

Why Now
  • Micro-cap speculation
  • 'Recovery Setup Building' narrative
  • Low stock price
Potential Catalysts
  • Reverse merger
  • Acquisition
  • Sudden influx of working capital
Key Risks
  • Zero revenue
  • No operations
  • Micro/SME cap - liquidity risk
  • Questionable management
  • No promoter holding
Institutional Activity

No FII or DII interest. Promoter holding is zero. Smart money is staying far away.

Macro Context

The Indian plastic industry is projected to grow, but Amerise isn't participating.

Cash Flow Quality

Free Cash Flow 5Y: ₹2.44 Cr. But with no revenue, this is irrelevant.

3–6 Month Outlook

Zero. Unless a miracle occurs, this company is going nowhere. Any positive movement will be short-lived and based on speculation, not fundamentals.

Primary Thesis Risk

Complete collapse of the company due to lack of operations and revenue.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

0.19%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

0.19%

Returns generated on total capital deployed

Oper. Profit Margin (5Y Avg)

N/A

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Amerise Biosciences Ltd Valuation Check

Poor

Price to Earnings (P/E)

99.19x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

23.37x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Poor

Promoter Holding

0.00%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-33.33%

Net profit growth vs same quarter last year

Revenue Growth (Quarterly YoY)

N/A

Revenue growth vs same quarter last year

Revenue Growth (5-Year CAGR)

N/A

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

15.63%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

15.63%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.00x

Total debt ÷ equity. Below 0.5 = financially healthy

Interest Coverage Ratio

N/A

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

2.44 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Amerise Biosciences Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of AMERISE across key market metrics for learning purposes.

Positive Indicators

4 factors identified

Excellent EPS Growth (15.63% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (15.63% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Debt-Free Balance Sheet (D/E: 0.00)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

6 factors identified

Below-Average Return on Equity (0.19%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (0.19%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Premium Valuation Risk (P/E: 99.19x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Profit Decline Concern (-33.33%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Low Promoter Commitment (0.00%)

Observation: Reduced promoter stake may indicate limited confidence.

Analysis: Low promoter holding may raise questions about management commitment.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Amerise Biosciences Ltd vs Plastic Products - Industrial Peers

Peer Comparison - Plastic Products - Industrial

Compare Amerise Biosciences Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
9.2/100
1
₹3.97
99.2
Average
0.19%
Poor
0.19%
Poor
0.0
Excellent
15.63%
Excellent
0.00%
53.6/100
3521
₹42365.85
50.0
Average
17.14%
Good
22.04%
Excellent
0.1
Excellent
14.56%
Good
13.64%
Good
1.02%
61.1/100
1533
₹38732.66
76.0
Average
14.89%
Average
19.71%
Good
0.1
Excellent
15.44%
Excellent
17.74%
Excellent
0.26%
43.6/100
3145
₹12031.71
82.3
Average
18.49%
Good
19.52%
Good
0.3
Excellent
0.08%
46.3/100
178
₹10944.52
25.0
Average
6.76%
Poor
8.77%
Poor
0.0
Excellent
4.12%
Average
6.77%
Good
1.13%
52.7/100
172
₹9836.32
23.4
Average
14.22%
Average
17.35%
Good
0.2
Excellent
18.02%
Excellent
8.81%
Good
0.63%
58.1/100
5814
₹8989.88
28.7
Average
15.00%
Good
20.57%
Excellent
0.0
Excellent
31.28%
Excellent
17.93%
Excellent
0.31%
60.3/100
5296
₹5906.41
37.5
Average
23.21%
Excellent
30.55%
Excellent
0.0
Excellent
44.08%
Excellent
18.66%
Excellent
0.00%
17.1/100
258
₹3009.44
129.7
Average
2.73%
Poor
3.85%
Poor
0.1
Excellent
-17.77%
Poor
9.06%
Good
0.18%
Jai Corp Ltd...
JAICORPLTD512237
53.4/100
114
₹2510.08
15.0
Average
4.10%
Poor
4.18%
Poor
0.0
Excellent
15.29%
Excellent
-0.35%
Poor
0.35%
60.6/100
17
₹1978.13
62.9
Average
39.70%
Excellent
44.66%
Excellent
0.4
Excellent
53.59%
Excellent
41.18%
Excellent
0.06%

Amerise Biosciences Ltd Quarterly Performance

Latest quarterly metrics for AMERISE — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

N/A

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-33.33%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

N/A

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

15.63%

Compounded annual net profit growth over 5 years

Amerise Biosciences Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for AMERISE — calculated from daily price history

43RSI 14
Neutral — RSI 43

Momentum is balanced — neither overbought nor oversold.

SMA 50
1
▲ Price above SMA 50 — Short-term bullish
SMA 200
1
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
88K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Amerise Biosciences Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Amerise Biosciences Ltd (AMERISE) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Amerise Biosciences Ltd

About AMERISE (Amerise Biosciences Ltd)

Amerise Biosciences Ltd is a fledgling enterprise venturing into the specialized field of industrial plastic products, currently laying the groundwork for future operations. While ...the company is in its nascent stages, the vision is to establish a robust manufacturing and distribution network catering to diverse industrial needs. Amerise aims to specialize in high-performance plastics, engineered for durability, resilience, and adaptability across various demanding applications. The core focus will be on creating custom solutions for sectors requiring superior materials, emphasizing innovation in plastic compound development and molding processes. Though currently focused on building infrastructure and developing key partnerships, Amerise Biosciences anticipates significant growth and impact as it moves towards full-scale production. The foundation of Amerise Biosciences' future success rests on a commitment to research and development, aimed at producing cutting-edge plastic products. The company intends to invest heavily in advanced technologies, including specialized extrusion and injection molding equipment, and a dedicated team of engineers and material scientists. This strategic focus will allow for the creation of specialized plastic components for a wide range of sectors, including automotive, aerospace, and construction. By incorporating sustainable practices into its manufacturing processes, Amerise Biosciences also aims to minimize its environmental impact, utilizing recycled materials and implementing energy-efficient technologies, furthering a commitment to responsible industry growth and resource management. Established with a refreshed purpose and vision, Amerise Biosciences Ltd leverages its corporate history as a launchpad for a new chapter in industrial plastics. Transitioning from previous ventures, the company has undergone a strategic re-alignment to concentrate on the burgeoning market for specialized plastic products. Headquartered in Ahmedabad, India, Amerise is strategically positioned to access a vibrant and diverse industrial ecosystem, offering substantial advantages in manufacturing and logistics. With a clear focus on establishing strong relationships with both suppliers and customers, Amerise Biosciences is dedicated to building a lasting legacy in the plastics industry through a commitment to quality, innovation, and customer satisfaction.

Company Details

Symbol:AMERISE
Industry:Plastic Products - Industrial
Sector:Plastic Products - Industrial

Key Leadership

Mr. Dineshkumar Tribhovanbhai Rathod
CFO, Chairman & Whole Time Director
Ms. Minal Vinodkumar Lakhlani
Company Secretary

AMERISE Share Price: Frequently Asked Questions

What is the current share price of Amerise Biosciences Ltd?

Amerise Biosciences Ltd (AMERISE) trades at ₹0.71 on NSE and BSE. Market cap ₹3.97 (Cr). Educational data only.

What is the P/E ratio of Amerise Biosciences Ltd?

Amerise Biosciences Ltd has a P/E of 99.19x vs industry average 23.37x.

What is the Bull Run score for Amerise Biosciences Ltd?

Amerise Biosciences Ltd has a Bull Run score of 9.2/100 based on 25+ financial parameters.

Does Amerise Biosciences Ltd pay dividends?

Amerise Biosciences Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Amerise Biosciences Ltd?

Amerise Biosciences Ltd has ROE of 0.19%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Amerise Biosciences Ltd?

Amerise Biosciences Ltd has debt-to-equity of 0.00.

Is Amerise Biosciences Ltd a good investment?

Bull Run gives Amerise Biosciences Ltd a score of 9.2/100. This is not investment advice — consult a SEBI-registered advisor.